Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 3833 - 3840 of 12082 results

Form I-9 Flexibility Updates
August 21, 2020| Blog| Viewpoint

Trends in COVID-Era Renewables Tax Credit Proposals
August 21, 2020| Blog| Viewpoint

With Release of New Guidance, FDA Signals It’s Serious About Enforcing Clinical Trial Data Requirements
August 20, 2020| Blog| Viewpoint

Danger on the Horizon: Detecting Early Signs of Trade Secret Theft by Competitors
August 20, 2020| Blog| Viewpoint

Bioethics in a Pandemic: Vaccine Distribution
August 19, 2020| Blog| Viewpoint

Update - USCIS Filing Fee Increases
August 19, 2020| Blog| Viewpoint
News & Press Releases
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
IP Strategist Daniel Brownstone Joins Mintz in New York
July 30, 2025
Daniel Brownstone has joined Mintz as a Member in the firm’s Intellectual Property Division, adding depth to the firm’s IP Prosecution Practice and contributing to its continued growth in the market. He will be based in the firm’s New York office.
Intelligize referenced a recent article by Mintz Member Jacob Hupart in its coverage of the ongoing court challenges to the Securities and Exchange Commission’s climate disclosure rule. Jacob’s piece examines the Eighth Circuit’s decision to hold litigation over the rule “in abeyance.”
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
